Peptide Synthesis Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Global Peptide Synthesis Market size is estimated at USD 0.95 billion in 2025, and is expected to reach USD 1.29 billion by 2030, at a CAGR of 6.35% during the forecast period (2025-2030).

Rising investments and substantial funding for genomics and proteomics research are driving the demand for peptides in drug discovery and therapeutic development. Owing to the rising demand for effective protein-based drugs for the proper treatment process, increasing investments, and significant funding for the research and development of genomics and proteomics in the biopharmaceutical industry, the market is expected to grow during the forecast period.

The increasing government funding to support research and developmental activities and drug discovery is expected to boost the growth of the market, as these investments drive the demand for peptides in genomics and proteomics research. According to the article published by the Department of Health and Aged Care, Australia, in March 2022, the Australian government invested USD 28.1 million from 2022-23 to 2025-26 to establish a new agency, Genomics Australia, to support the integration of genomic medicine as a standard of healthcare in Australia. Such investments by governments are also expected to propel market growth.

There is a rising demand for peptide synthesis as it is useful for proteomics-based biomarker discovery and validation on specific diseases, which is anticipated to boost the market’s growth. For instance, according to an article published by Nature Journal in June 2023, the preference for the PepQuant library over high-resolution mass spectrometry for human blood biomarker discovery expanded the utilization of peptide libraries. This contributes to the increasing research and developments concerning disease therapeutics that use peptides, thus contributing to the market's growth.

Advancements in peptide synthesizer technology, such as microwave-assisted SPPS (solid phase peptide synthesis), have significantly enhanced peptide production. These innovations offer faster synthesis times, increased automation, improved quality, greater scalability, real-time monitoring, and reduced solvent usage. These innovations can accelerate the development of new peptide-based therapeutics, making peptide synthesis more efficient and cost-effective.

The rising benefits of peptide synthesizers, such as their high efficiency and scalability, are anticipated to boost market growth. For instance, according to the study published in Nature Communications in December 2023, peptide synthesis was executed using a Liberty PRIME 2.0 automated microwave peptide synthesizer at a 0.1 mmol scale, incorporating one-pot coupling and deprotection steps. This peptide synthesizer resulted in a highly efficient, pure, and scalable process, reducing waste by up to 95% and requiring only 10-15% of the standard base amount. Therefore, the advantages of effectively conserving solvents with advanced peptide synthesizers are anticipated to increase the adoption of innovative equipment and drive market growth.

However, large-scale synthesis often encounters scalability issues, leading to production challenges and increased costs. Large-scale peptide synthesis demands huge capital, equipment, and skilled labor. A lack of skilled workforce can become a challenge and, hence, limit the growth of the market.

Peptide Synthesis Market Trends

The Segment for Solid-phase Peptide Synthesis (SPPS) Holds a Significant Market Share

Solid-phase peptide synthesis (SPPS) is a pivotal technique in the production of peptides, where the peptide chain is built on a solid support, typically a resin. This method has revolutionized peptide synthesis by streamlining automation and purification processes, making it a staple in research and industrial applications.

SPPS is especially notable for its efficiency in producing longer peptides, such as those used in diabetes treatments, which can be challenging to synthesize using liquid-phase methods due to complex purification requirements.

The growing demand for peptides has led to considerable expansion in SPPS production capabilities. For instance, in January 2024, WuXi AppTec reported commissioning new peptide manufacturing plants in Changzhou and Taixing, China. This expansion increased its total reactor volume to 32,000 liters, addressing the increased global demand for peptide therapeutics.

Similarly, in September 2023, CordenPharma International inaugurated an expanded SPPS manufacturing facility at CordenPharma Colorado, enhancing its capacity to meet global demand. This facility is the largest SPPS production site worldwide, with upgraded technology that boosts efficiency and throughput.

SPPS remains a critical technology in peptide production, particularly for the pharmaceutical industry. The increasing demand for peptide drugs and the need for more sustainable manufacturing practices drive significant innovations and expansions in SPPS. As the market continues to address environmental challenges and improve efficiency, SPPS is set to maintain its pivotal role in drug development and other applications.

North America is Expected to Record Significant Growth Over the Forecast Period

The North American market for peptide synthesis is expected to grow due to factors such as strong R&D investment in biotechnology and pharmaceuticals, advanced healthcare infrastructure, the presence of major pharmaceutical and biopharmaceutical companies, and the increasing prevalence of chronic diseases.

The presence of a large number of academic and research institutes and heavy funding from the government and private entities are expected to result in several new developments in the region, further adding to the growth of the market as many of these research institutes are working on novel therapies involving therapeutic peptides.

The rising funding from the National Institute of Health on genomic research is anticipated to propel market growth over the forecast period. For instance, in September 2023, the National Institute of Health (NIH) allocated around USD 5.8 million for a five-year initiative to establish an educational center focusing on computational genomics and data science. This aims to broaden educational and research horizons, particularly targeting students from historically marginalized backgrounds in the biomedical field. Therefore, such huge funding for genomics is anticipated to increase the adoption of peptide synthesis for genomics.

Some of the world's largest pharmaceutical and biopharmaceutical companies are present in the United States. In September 2023, Corden Pharma, a key company in active pharmaceutical ingredients (APIs), excipients, drug products, and packaging services, inaugurated an expanded commercial peptide production capacity with newly upgraded facilities at its Colorado site. This expansion reinforced Corden Pharma's status as the premier large-scale peptide CDMO partner for the pharmaceutical and biotech industries.

Therefore, owing to the high burden of chronic diseases, well-established and robust healthcare infrastructure, rising investments in genomics and proteomics, and significant investment in research and development activities, the United States is expected to hold a significant share of the peptide synthesis market over the forecast period.

Peptide Synthesis Industry Overview

The peptide synthesis market is competitive in nature, with several major players. Some companies are expanding their market position by adopting various strategies, such as acquisitions, mergers, and research collaborations, while others are introducing new products to maintain their market share. Some of the key market players include Bachem, Merck KGaA, Novozymes, and Thermos Fisher.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support